Core Insights - Centene reported revenue of $49.69 billion for the quarter ended September 2025, reflecting an 18.2% increase year-over-year and a surprise of +4.35% over the Zacks Consensus Estimate of $47.62 billion [1] - The earnings per share (EPS) was $0.50, a significant decrease from $1.62 in the same quarter last year, with an EPS surprise of +338.1% compared to the consensus estimate of -$0.21 [1] Financial Performance Metrics - Total Medical Health Benefits loss ratio was reported at 92.7%, slightly better than the estimated 93% [4] - Membership in High Acuity Medicaid was 1.59 million, close to the estimated 1.6 million [4] - Medicare PDP membership reached 7.97 million, exceeding the average estimate of 7.88 million [4] - Medicare membership was reported at 1.01 million, slightly below the estimated 1.03 million [4] Revenue Breakdown - Premium revenues totaled $44.13 billion, surpassing the average estimate of $42.81 billion, with a year-over-year increase of +22.2% [4] - Service revenues were $772 million, slightly below the average estimate of $727.33 million, representing a -1.5% change year-over-year [4] - Combined premium and service revenues were $44.9 billion, exceeding the average estimate of $43.54 billion, with a year-over-year increase of +21.7% [4] - Premium tax revenues were $4.79 billion, above the average estimate of $4.07 billion, showing a -6.5% change year-over-year [4] - Medicaid premium and service revenues were $23.17 billion, exceeding the estimate of $22.33 billion, with an +8.7% change year-over-year [4] - Commercial premium and service revenues reached $10.99 billion, surpassing the estimate of $10.41 billion, reflecting a +26.5% year-over-year increase [4] - Medicare premium and service revenues were $9.39 billion, slightly below the average estimate of $9.53 billion, with a significant +66.4% change year-over-year [4] - Other premium and service revenues totaled $1.34 billion, exceeding the estimate of $1.25 billion, representing a +7.8% change year-over-year [4]

Core Insights - Molina (MOH) is expected to report quarterly earnings of $3.97 per share, reflecting a decline of 33.9% year-over-year, while revenues are forecasted to reach $10.9 billion, an increase of 5.4% year-over-year [1] - The consensus EPS estimate has been revised upward by 7.8% in the past 30 days, indicating a reassessment of initial estimates by analysts [1][2] Revenue Projections - Analysts predict 'Revenue- Premium revenue' at $10.31 billion, a change of +6.3% from the prior-year quarter [4] - 'Revenue- Premium tax revenue' is estimated to be $474.87 million, indicating a decline of -6.5% year-over-year [4] - 'Revenue- Premium revenue- Medicare' is projected to reach $1.48 billion, reflecting an increase of +8% from the prior-year quarter [4] - The consensus estimate for 'Revenue- Premium revenue- Medicaid' stands at $7.66 billion, suggesting a slight decline of -0.1% year-over-year [5] Membership and MCR Estimates - 'Ending Membership by Program - Total' is expected to be 5.74 million, up from 5.60 million year-over-year [6] - 'MCR - Total' is projected at 90.3%, an increase from 89.2% in the previous year [5] - 'MCR - Medicare' is expected to be 87.0%, down from 89.6% in the same quarter last year [5] - 'MCR - Marketplace' is forecasted at 84.7%, up from 73.0% year-over-year [6] - 'Ending Membership by Program - Medicaid' is estimated to reach 4.80 million, down from 4.94 million year-over-year [6] - 'Ending Membership by Program - Medicare' is projected at 263.02 thousand, an increase from 247.00 thousand year-over-year [7] - 'Ending Membership by Program - Marketplaces' is expected to be 659.47 thousand, up from 410.00 thousand year-over-year [7] Market Performance - Molina shares have returned +8.6% over the past month, outperforming the Zacks S&P 500 composite's +1.2% change [8] - Despite recent performance, Molina holds a Zacks Rank 5 (Strong Sell), indicating expectations of underperformance relative to the overall market in the near future [8]

Core Viewpoint - The significant buying activity in UnitedHealth Group (UNH) by prominent investors, including Warren Buffett's Berkshire Hathaway, indicates a potential bottoming out of the stock after a severe decline due to negative events and market sentiment [1][2][3]. Group 1: Investment Activity - Berkshire Hathaway purchased approximately $1.57 billion worth of UNH shares, while Dodge & Cox acquired about $1.87 billion [2]. - Other notable investors included Renaissance Technologies with $500 million, David Tepper with $764 million, and Michael Burry who bought options and stock [1][2]. - The collective buying from these high-profile investors has instilled confidence in retail investors to follow suit [1][2]. Group 2: Stock Performance and Market Reaction - Following the disclosure of Buffett's investment, UNH's stock surged by 12%, reclaiming a price above $300 [3]. - The stock had previously experienced a dramatic decline of 60% due to a series of negative events, including a significant earnings miss and the resignation of its CEO [1][10]. Group 3: Company Fundamentals and Market Position - UNH is the largest health insurance company in the U.S., covering nearly 50 million people, which makes its stability crucial for the healthcare system [13]. - The company holds a 30% market share in Medicare and is the second-largest in Medicaid, indicating its significant role in the healthcare landscape [13]. - Analysts project an EPS of approximately $25 for the next year, with the stock trading at about 12 times earnings, alongside a 3% dividend yield and a $12 billion share buyback plan [13][15]. Group 4: Future Outlook - The consensus among investors is that UNH has already priced in the worst-case scenarios, and any improvement in business operations could lead to substantial stock price recovery [12][15]. - The presence of a safety net in the form of an 8% shareholder return through dividends and buybacks further supports the investment thesis for UNH [15].

Core Viewpoint - UBS maintains a "Buy" rating on Elevance Health with a target price of $435, indicating a potential upside of nearly 53% from the current closing price of $283.48 [1] Financial Performance - Elevance Health reported Q2 revenue of $49.8 billion, exceeding market expectations [1] - Adjusted earnings per share (EPS) for the quarter were $8.84, in line with market expectations [1] Earnings Guidance - The company lowered its full-year EPS guidance by $4.50, which translates to a pre-tax profit reduction of $1.3 billion [1] - Elevance Health raised its 2025 medical loss ratio forecast by 90 basis points [1] Market Factors - The increase in medical loss ratio expectations is attributed to unfavorable cost trends in the Affordable Care Act (ACA) exchanges and Medicaid business [1] - Despite the challenges, UBS remains optimistic about the potential profitability and growth in the commercial insurance and Carelon business segments [1]

Core Viewpoint - UBS reiterated a "Buy" rating for Elevance Health (ELV.US) with a target price of $435, indicating a potential upside of nearly 53% from the recent closing price of $283.48 [1] Financial Performance - Elevance Health reported Q2 revenue of $49.8 billion, exceeding market expectations [1] - Adjusted earnings per share (EPS) for Q2 were $8.84, in line with market expectations [1] - The company lowered its full-year EPS forecast by $4.50, equating to a pre-tax profit reduction of $1.3 billion [1] Future Projections - Elevance Health raised its 2025 medical loss ratio forecast by 90 basis points [1] - The increase in medical loss ratio expectations is attributed to unfavorable cost trends in the Affordable Care Act (ACA) transactions and Medicaid business [1] Investment Rationale - UBS maintains a "Buy" rating due to the potential profitability stability and growth opportunities in the commercial insurance and Carelon business segments, despite the raised medical loss ratio expectations [1]

Group 1: Impact on Healthcare Sector - The "Big and Beautiful" bill is expected to cut approximately $900 billion in Medicaid spending over the coming years, reversing many advancements made during the Biden and Obama administrations in healthcare [4] - The bill introduces stricter requirements for Medicaid beneficiaries, potentially leading to millions losing their healthcare coverage [5] - Companies heavily exposed to Medicaid, such as Elevance Health, Centene, and Molina Healthcare, are likely to see a direct impact on their revenues due to a decrease in Medicaid enrollment [5][6] Group 2: Effects on Renewable Energy Industry - The bill cancels several clean energy incentives from the Biden administration, imposing restrictions on solar and wind energy while encouraging fossil fuel production [7] - Changes in tax measures are expected to increase the burden on the renewable energy sector by approximately $4 billion to $7 billion [8] - The bill threatens around $450 billion in infrastructure investments in the renewable sector, potentially leading to the loss of about 300 gigawatts of solar and wind projects over the next decade [8] Group 3: Benefits to Corporations and High-Income Individuals - The bill reinstates tax policies that allow businesses to fully deduct equipment costs in the year of purchase, benefiting organizations like the U.S. Chamber of Commerce [11] - High-income households are projected to see a net income increase of nearly $13,000 after taxes and transfers, while middle-income families will see a smaller increase of $1,430 [12] - The bill provides additional tax incentives for semiconductor manufacturers building facilities in the U.S., aiming to stimulate investment in the manufacturing sector [11]